Patients with inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), have heightened susceptibility to several infections.1 Advances in IBD treatment options include small molecule, anti-tumor necrosis factor agents, and non-tumor necrosis factor biologics, which have greater rates of clinical remission than conventional therapy but can result in increased risk of infections.2 This evidence concerns the gene TNF and infection.